Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

R. Westin, Jason; O. Oluwole, Olalekan; José Kersten, Marie; B. Miklos, David; Perales, Miguel‐Angel; Ghobadi, Armin; P. Rapoport, Aaron; Sureda, Anna; A. Jacobson, Caron; Farooq, Umar; van Meerten, Tom; L. Ulrickson, Matthew; Elsawy, Mahmoud; A. Leslie, Lori; Chaganti, Sridhar; Dickinson, Michael; Dorritie, Kathleen; M. Reagan, Patrick; P. McGuirk, Joseph; Song, Kevin; A. Riedell, Peter; C. Minnema, Monique; Yang, Yin; Vardhanabhuti, Saran; Filosto, Simone; Cheng, Paul; Shahani, Shilpa; Schupp, Marco; To, Christina; L. Locke, Frederick

doi:10.1056/nejmoa2301665

Public

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Published in New England Journal of Medicine • Jun 5, 2023

Authors:

Jason R. Westin

Olalekan O. Oluwole

Marie José Kersten

Abstract

BACKGROUND: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longe...

Subject

Medicine

Chemoimmunotherapy

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!